An integrated methodological roadmap for real-world biomarker studies: advancing oncology precision medicine through...

The selection of biomarker-specific patient populations is essential in targeted cancer therapies to enhance precision and efficacy. To ensure a successful launch, it is vital to promote awareness and adoption of biomarker testing at diagnosis, tailor implementation strategies to accommodate local variations, and ensure testing is accessible and reimbursed. An integrated evidence generation plan should address critical questions, including the prevalence of biomarker expression and agreement between local and central labs, across different platforms, antibodies and pathologists. Furthermore, understanding prognostic effects and associations with other biomarkers is of considerable interest. Real-world studies (RWS) play a pivotal role in addressing these questions but are inherently challenged by confounding factors, biases (e.g. immortal time bias), missing data, agreement assessment complexities, and low biomarker expression prevalence. This manuscript provides an integrated methodological roadmap for designing and analyzing RWS. We address key challenges by integrating robust statistical methodologies with advanced machine learning (ML) methods. Core methods discussed include the use of time-dependent Cox models to mitigate immortal time bias, inverse probability of biomarker weighting to adjust for confounding, and ML-based tree ensemble approaches to model complex relationships between covariates and outcomes and handle missing data. By systematically applying this integrated roadmap, we demonstrate how to enhance the validity and robustness of RW biomarker research. This approach overcomes common analytical pitfalls, enabling more reliable evidence generation for clinical decision-making. Ultimately, this roadmap helps drive precision oncology forward by ensuring that biomarker-driven therapeutic strategies are based on sound, high-quality RW evidence.